VIVO diagnostics buys Genyca and leads the way in precision diagnostics

21/06/2019
Diego Gutiérrez
VIVO diagnostics buys Genyca and leads the way in precision diagnostics

The VIVO diagnóstico group takes a further step on its way to becoming the leading company in precision diagnostics in Spain. The company enters the field of genetics, and has just formalised the incorporation of the Genyca group, a laboratory specialising in molecular genetics.

VIVID DIAGNOSIS

VIVO diagnosis is a company specialising in diagnostic imaging and telemedicineThe new system will be able to combine in vivo and in vitro diagnostics through the use of artificial intelligence and Big Data tools.

To this end, it carries out an analysis based on prediction, prevention and personalisation. For the group, it is essential to identify any signs or probability of change in people's state of health as early as possible and as accurately as possible.

Ahora, además, gracias a Genyca, se va a incorporar pruebas de diagnóstico genético molecular para ayudar a estudiar el genoma de cada individuo, también denominado por algunos líderes del sector como el “software del cuerpo humano”.

However, this is not VIVO diagnostics' first operation on the market. Its journey towards precision diagnostics and service to the public began two years ago with two other operations. mergers and acquisitions . The following are some of the issues that we set out below.

Dima Clinic

This clinic leader in breast pathology was the first of these. Dima Clinic has expert breast surgeons, radiologists and oncologists who offer comprehensive breast diagnosis and treatment.

Its experts assess each patient and her risk factors, using both mammography and breast ultrasound and obtaining the analysis of the results in an average of 2-3 days, as in these cases time is of the essence.

Fence

Después vino Cerco, una compañía referente en el mercado andaluz y with a strong presence in the world of clinical research.

In addition to mammography and breast ultrasound, its services include magnetic resonance imaging, CT and densitometry, with the aim of offering patients the highest diagnostic quality and reliability.

Lastest news

The State of Technology M&A in Spain | October 2026 analysis

En octubre de 2026 hubo 37 operaciones de M&A tecnológico en España: 16 fueron adquisiciones corporativas, inversiones de private equity, fusiones o tomas de participación, y 21 fueron rondas de venture capital. El 62,2% de las operaciones (23 de 37) fueron...

Webinar | How much does your business depend on you?

IMPORTANT INFORMATION: Registration for and participation in the webinars are completely anonymous to third parties. If, for a month, you were unable to have a say in important decisions, what would happen in your company? Your company can grow, be profitable and have good...

Notable technology M&A deals in Spain | September 2026 Analysis

Technology M&A in Spain totalled 61 identified transactions by the end of September 2026, the highest figure in the monthly series we have been publishing since May. Of these, 41 were acquisitions, private equity investments, asset purchases, joint ventures or takeovers...

Baker Tilly advises Invelon on the acquisition of byAR

In September 2026, Invelon, a Spanish technology company specialising in virtual, augmented and mixed reality, completed the acquisition of a majority stake in byAR, a Portuguese company specialising in museum exhibitions and the development of spaces...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?